NCT01857037已完成不适用
Detection and Localization of Prostate Cancer Local Recurrences After Radiation Therapy Using Histoscanning™ and Multiparametric MRI
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Evaluation of Histoscanning™ after radiation therapy in comparison to random and targeted biopsy.
研究概览
简要总结
Inclusion criteria:
- Patients with biochemical recurrence (Phoenix criteria: PSA nadir + 2 ng/ml) after radiation therapy for prostate cancer addressed for prostate biopsy OR
- Patients referred to our institution for biopsy-proven local recurrence after radiation therapy for prostate cancer but needing a re-assessment with biopsy (insufficient number of biopsy and/or imprecise location of positive biopsy and/or questionable diagnostic of recurrence)
Study Design:
- Included patients will undergo an endorectal US examination with a Histoscanning™ acquisition and a multiparametric (T2-weighted, diffusion-weighted and dynamic contrast-enhanced) MRI.
- Two independent operators will separately define suspicious focal lesion on Histoscanning™ images and on MR images.
- Random biopsies (at least 2 cores) will be performed in sextants negative at Histoscanning™ and at MRI ; In sextants positive at Histoscanning™ and/or at MRI, targeted biopsies will be performed in the suspicious part of the sextant (at least two cores per suspicious lesion).
- Histoscanning™ and MRI results will be compared to biopsy results.
A total of 30 patients will be included
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients with biochemical recurrence (Phoenix criteria: PSA nadir + 2 ng/ml) after radiation therapy for prostate cancer addressed for prostate biopsy OR Patients referred to our institution for biopsy-proven local recurrence after radiation therapy for prostate cancer but needing a re-assessment with biopsy (insufficient number of biopsy and/or imprecise location of positive biopsy and/or questionable diagnostic of recurrence)
- •IRB-approved informed consent signed
排除标准
- •Contraindication to MRI
- •Contraindication to endorectal examination
- •Contraindication to prostate biopsy
- •History of allergy to gadolinium chelates
研究组 & 干预措施
Single arm
Other
Single arm
干预措施: Histoscanning™ and multiparametric MRI (Other)
结局指标
主要结局
Evaluation of Histoscanning™ after radiation therapy in comparison to random and targeted biopsy.
时间窗: 1 day
Histoscanning and biopsy findings will be compared on a sextant by sextant basis. A mixed effects logistic regression model (with fixed and random effects) will be used to model the sensitivity and specificity of Histoscanning to correctly identify the presence or absence of cancer into prostate sextants.
次要结局
- Evaluation of multiparametric MRI after radiation therapy in comparison to random and targeted biopsy.(1 day)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate CancerProstate CancerNCT01558427University Hospital, Ghent62
已完成
不适用
Detection of Clinically Significant Prostate Cancer With 18F-DCFPyL PET/MRNeoplasm, ProstateNCT03149861University Health Network, Toronto56
招募中
不适用
Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate CancerCastration-resistant Metastatic Prostate CancerTreated by 177Lutetium-PSMA-617 (Lu-PSMA)NCT06600802Centre Jean Perrin120
Unknown
3 期
A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-DocetaxelAdenocarcinoma of the ProstateNCT00764166Assistance Publique - Hôpitaux de Paris254
招募中
Unknown
Detection of clinically significant prostate cancer with MRI-TRUS fusion image-guided biopsy: comparison of the evaluation system (PI-RADS category vs. PI-RADS + US evalutaion)Suspected prostate cancerJPRN-UMIN000050631Tokai University80
